Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

107.04 -1.91 (-1.75%)
Streaming Delayed Price Updated: 3:30 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
45 46 Next >
Metastatic Hormone Refractory Prostate Cancer Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies – Novartis, Astrazeneca, Merck, Clovis Oncology Inc Arcus Bioscience
Via AB Newswire
Metastatic Hepatocellular Carcinoma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies |Companies – Astrazeneca, Roche, Novartis, Chugai Pharmaceuticals, BeiGene
Via AB Newswire
Biologics and Biosimilars Market Is Touching New Level – A Comprehensive Study with Key Players Amgen, AbbVie, Sanofi-Aventis
Biologics and Biosimilar Market Size, Status and Forecast 2028 
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union. 
Via The Motley Fool
Rett Syndrome Market to Observe Stupendous Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Neurolixis, Vyant Bio, Prilenia, StrideBio, Novartis, Ultragenyx
Via AB Newswire
Complicated Urinary Tract Infection (cUTI) Market to Witness Growth by 2032, Estimates DelveInsight| Meiji Seika Pharma, Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt
Via AB Newswire
Alcoholic Hepatitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Durect Corporation, Novartis, Intercept Pharma, Gilead Sciences
Via AB Newswire
Beta Thalassemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Novartis, Hoffmann-La Roche, Vertex Pharma, Bristol-Myers Squibb, Sanofi, HemaQues
Via AB Newswire
Neurofibromatosis Type-2 Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies – AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others
Via AB Newswire
Netherton Syndrome Pipeline, NDA Approvals, Emerging Drugs and Clinical Trials (2023) | Companies – Novartis, Timber Pharma, Bridge Biopharma, Evotec AG, Dermelix Biotherapeutics, Krystal Biotech.
Via AB Newswire
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that  
Via Benzinga
Stock Market Rally Runs Through Hawkish Fed; Adobe, Lennar, Oracle, UnitedHealth In Focus: Weekly Review
Stocks kept powering higher despite, but the Nasdaq is looking extended. 
Via Investor's Business Daily
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A. 
Via Investor's Business Daily
Cryopyrin Associated Periodic Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 |Companies – Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics
Via AB Newswire
Craniopharyngioma Pipeline, Clinical Trials, and Key Companies|Companies – Novartis, Blaze Bioscience, Bristol Myers Squibb, INSYS Therapeutics, Zafgen
Via AB Newswire
Paroxysmal Nocturnal Hemoglobinuria Market and Epidemiology 2032 by DelveInsight | Roche, Alexion Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceutical
Via AB Newswire
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
Ocular Melanoma Market expected to rise | Companies – Eli Lilly & Co, Spectrum Pharmaceuticals Inc, Novartis AG, Bayer, AstraZeneca plc, Merck, Amgen, Pfizer Inc, Roche, expected to drive market
Via AB Newswire
Hepatocellular Carcinoma Market and Epidemiology 2032: Treatment Therapies, FDA Approvals, Companies and Market Forecasting by DelveInsight | AbbVie, Bayer, Novartis, Bristol-Myers Squibb, Takeda
Via AB Newswire
Exposures Product Safety
Nasopharyngeal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Incyte, BeiGene, Klus Pharma, Merck, Roche, Novartis, Akeso Pharma
Via AB Newswire
Exposures Product Safety
Lupus Nephritis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Novartis, RemeGen, Roche, Annexon, Argenx, AstraZeneca, Aurinia
Via AB Newswire
Cystic Fibrosis Pipeline, Clinical Trials, and Key Companies|Companies – Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma
Via AB Newswire
Ophthalmoplegia Market expected to rise | Companies – Abbott, Novartis AG, ZEISS International, Valeant Pharmaceuticals International, ALLERGAN, Johnson & Johnson, expected to drive market
Via AB Newswire
KRAS Inhibitors Market to Witness Growth by 2032, Estimates DelveInsight | Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio
Via AB Newswire
Novartis Stock Screams Value After Chinook Therapeutics Buyout
Following a buyout of Chinook Therapeutics, Novartis slipped less than 1%. This speaks to the growth potential of Chinook and ongoing value of Novartis stock. 
Via MarketBeat
IgA Nephropathy Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Alnylam, RemeGen, Novartis, Visterra/ Otsuka, Vera Therapeutics, Omeros Corp.
Via AB Newswire
Exposures Product Safety
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook
Chinook Therapeutics is about to be acquired by Novartis. News of this deal hasn't stopped Muddy Waters from betting against KDNY stock. 
Via InvestorPlace
Bone Neoplasms Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Amgen, Novartis, Roche, Merck, Luye Pharma, Bayer, Pfizer.
Via AB Newswire
Opioid-Induced Constipation Market expected to rise | Companies – Cosmo Pharmaceuticals, Shionogi & Co., Merck & Co, Novartis AG, AstraZeneca plc, Bausch Health Companies, expected to boost the market
Via AB Newswire
2022 R&D Spending and Intensity Benchmarks
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D... 
Via PRLog
Topics Supply Chain
Exposures Supply Chain
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.